Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI versus FF in persistent asthma
NL-OMON40121Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and vilanterol in asthma (3 arms), sponsored by GSK. Primary endpoint: Weighted mean serial FEV1 over 0 to 24 hours post-dose at end of treatment. Started Nov 2012; status: active, not recruiting.
02
Drugs
fluticasonevilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON40121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40121.